Clinical trials
Triple Negative Breast Neoplasms trials in the United States with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2017 | 4 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 4 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 11 |
| Completed | 7 |
| Withdrawn | 5 |
| Active, not recruiting | 4 |
| Not yet recruiting | 1 |
| Suspended | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 4 |
| City of Hope Medical Center | 3 |
| Ohio State University Comprehensive Cancer Center | 3 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Baylor Research Institute | 1 |
| Brigham and Women's Hospital | 1 |
| Duke University | 1 |
| Emory University | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Indiana University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Triple Negative Breast Neoplasms | 30 |
| Breast Neoplasms | 17 |
| Ovarian Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Carcinoma, Renal Cell | 2 |
| Colonic Neoplasms | 2 |
| Endometrial Neoplasms | 2 |
| Inflammatory Breast Neoplasms | 2 |
| Melanoma | 2 |
| Vaginal Neoplasms | 2 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.